Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow aspirate + bone marrow aspirate concentrate
- Development stage
- Unknown
- Lead developer
- Apeiron Research Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intranasal
01
Overview
Autologous bone marrow aspirate (BMA) + bone marrow aspirate concentrate (BMAC) is an investigational autologous cell therapy combination being developed by Apeiron Research Center, in collaboration with the University of Colorado Boulder, for the treatment of Parkinson's disease and Parkinson-plus syndromes (atypical parkinsonism). The therapeutic protocol involves the same-day collection of the patient's bone marrow, followed by the administration of unprocessed, filtered aspirate (BMA) intravenously and a centrifuged concentrate (BMAC) intranasally. This dual-delivery method is designed to provide a high concentration of mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and bioactive growth factors to the systemic circulation and directly to the central nervous system via the nasal mucosa, bypassing the blood-brain barrier. The therapy aims to exert neuroprotective, immunomodulatory, and epigenetic effects to slow disease progression and reduce neuroinflammation.
- Other names
- BMA + BMACautologous stem cells
Beyond the preview
Go deeper on autologous bone marrow aspirate + bone marrow aspirate concentrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow aspirate + bone marrow aspirate concentrate.